Study of SGN-PDL1V in Advanced Solid Tumors

Phase 1

Recruiting

• Conditions: Malignant melanoma, Ovarian cancer, Squamous cell carcinoma of head and neck, Triple negative breast cancer, Oesophageal squamous cell carcinoma, Non-small cell lung cancer, Gastric cancer, Head and neck squamous cell carcinoma; MedDRA version: 21.1Level: PTClassification code: 10025650Term: Malignant melanoma Class: 100000004864; MedDRA version: 20.0Level: PTClassification code: 10075566Term: Triple negative breast cancer Class: 100000004864; MedDRA version: 21.1Level: PTClassification code: 10067821Term: Head and neck cancer Class: 100000004864; MedDRA version: 21.0Level: PTClassification code: 10060121Term: Squamous cell carcinoma of head and neck Class: 100000004864; MedDRA version: 21.0Level: PTClassification code: 10061534Term: Oesophageal squamous cell carcinoma Class: 100000004864; MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864; MedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864; Therapeutic area: Diseases [C] - Neoplasms [C04]

• Registration Number: CTIS2023-506604-18-00
• Lead Sponsor: Seagen Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-09-15
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 322

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified